Impetigo is a superficial bacterial skin infection, often seen as crusted lesions. Treatment depends on the number and extent of lesions, whether deeper ecthyma is present and the likely bacteria. Oral cephalexin can be one prescription option for selected extensive presentations, but small localized outbreaks often have a different approach using topical treatment.
This page focuses on the decision between oral and topical care. The cephalexin versus mupirocin comparison covers drug-specific differences; the skin infection hub provides broader context. Neither the presence of honey-colored crusts nor a product listing confirms that a child or adult needs oral cephalexin.
Impetigo spreads through close contact and shared items. Clinical review matters when lesions are widespread, recurrent, severe, accompanied by fever or not responding as expected. People with a prescription should follow the exact schedule and ask about lesion care and return-to-school or work policies rather than sharing leftover antibiotics.
Impetigo is a superficial bacterial skin infection, often with crusted lesions. Limited impetigo and widespread lesions do not automatically need the same approach. IDSA supports topical antimicrobial treatment for localized disease; numerous lesions, outbreaks affecting multiple people or deeper ecthyma can justify an oral antibiotic based on the clinical situation.
Cephalexin is one potential oral option when the suspected or identified bacteria are susceptible. It is not an automatic treatment for every crusted rash, and a suspected MRSA pattern or recurrent treatment failure may prompt cultures or a different approach. The decision between systemic and topical treatment should be based on examination rather than consumer preference for pills or cream.
Care planning also involves hand hygiene, cleaning shared items, covering lesions when advised and following local school or work policies. Family members should not share antibiotics, even when their lesions appear similar.
| Prescription or diagnosis question | Related Core guide | What it helps distinguish |
|---|---|---|
| Is this localized impetigo or a broader skin infection? | Skin infection patterns | Extent and diagnosis |
| What does topical mupirocin treat differently? | Oral versus topical treatment | Distinct routes and product indications |
| How does staphylococcal susceptibility matter? | MSSA context | When cephalexin might be appropriate |
| Can MRSA alter the treatment plan? | MRSA limits | Why cephalexin is not a reliable MRSA agent |
| How are pediatric liquid prescriptions verified? | Pediatric prescription review | Weight and concentration concerns |
| When should spreading disease be assessed? | Prompt examination | Widespread, severe or worsening lesions |
Impetigo commonly involves superficial lesions that break and crust; ecthyma extends more deeply and may leave ulcers. Their appearance can overlap with eczema, cold sores and other skin problems. A clinician uses lesion appearance, location, spread and sometimes cultures when the cause is uncertain.
Distinguishing ecthyma is important because its management is not identical to a few superficial impetigo spots. The assessment also considers exposure and whether multiple members of a household have similar lesions.
IDSA guidance supports topical treatment for limited impetigo, while numerous lesions or an outbreak affecting several people may lead to oral therapy. Mupirocin is a topical antibiotic; oral cephalexin reaches tissues systemically and has its own adverse-effect considerations. If more than one child or household member develops crusted lesions, the possibility of transmission changes practical advice. The prescriber may recommend covering lesions, hand hygiene, cleaning frequently touched items and considering whether oral therapy is warranted for the outbreak. Family members should not share one person’s antibiotic bottle because dosing and diagnoses can differ.
Putting both therapies into a generic “impetigo antibiotics” list hides the key decision: localized versus widespread or deeper disease. This page is about that clinical route, not about ranking brands or retail prices. A lesion that does not heal as expected may need evaluation for another diagnosis or a bacterial culture, rather than applying multiple creams or expanding the oral antibiotic regimen without review.
A clinician may choose oral cephalexin for broader impetigo or ecthyma when likely or identified organisms are susceptible and the patient can use a cephalosporin. The clinician considers lesion burden, history, potential MRSA, medication allergies and practical ability to follow treatment.
Cephalexin should not be presented as a required step for every small lesion. A prescription is specific to that case; repeating it for a family member with a new rash is not appropriate.
Impetigo can involve Staphylococcus aureus or streptococci. MRSA risk, outbreaks with uncertain organisms or failed initial care may justify further testing or a change in treatment. Cephalexin is not reliable for MRSA, so blind escalation is not a safe response to nonimprovement.
Read the MRSA limitation guide and the susceptible staph discussion for the distinct organism questions behind an antibiotic selection.
When the patient is a child, age, weight, concentration and ability to take an oral medication affect prescribing and dispensing. The pediatric dosage guide explains label frameworks without calculating an individual dose.
Liquid cephalexin must be measured using the supplied appropriate device. A change from 125 mg/5 mL to 250 mg/5 mL cannot be handled by copying an old milliliter instruction without pharmacist confirmation.
Hand hygiene, keeping lesions clean and covered when advised, avoiding shared towels and following school or childcare policies can reduce spread. These measures complement treatment; they do not replace a prescribed antibiotic when oral therapy is indicated.
Seek care if a lesion becomes rapidly painful, redness spreads, fever appears or the patient seems systemically unwell. Those are not situations for ordering another medication without assessment.
The written order must identify the intended oral product and regimen. Use the prescription guide for fulfillment questions and suspension product information if a liquid was prescribed.
A pharmacy can clarify strengths, concentrations and instructions, but it should not be asked to decide whether topical therapy or oral antibiotics are indicated without a clinician’s assessment.
Ask how many lesions are present, whether any involve deeper ecthyma and whether other household members are affected. The clinician may consider whether a local ointment is sufficient or whether systemic therapy is reasonable because of extent or transmission considerations. This decision is clinical, not a comparison of retail package sizes.
If the diagnosis is uncertain, lesions recur or treatment fails, a clinician may assess for resistant bacteria or another condition that resembles impetigo. A topical product should not be applied to large areas or mixed with another antibiotic without applicable directions. A child’s oral suspension must have product-specific concentration and measured-volume instructions.
A pharmacy can dispense the prescribed cephalexin or mupirocin presentation but cannot determine from a checkout cart whether the lesions have become extensive or deep. A licensed clinician should review fever, increasing pain, rapidly spreading involvement or lack of response.
Any partner-store link is commercial information only; it neither validates the diagnosis nor certifies that a particular oral or topical medicine is appropriate for the person with the rash.
Localized impetigo may be treated topically, whereas numerous lesions, ecthyma and selected outbreaks can lead to clinician-prescribed oral therapy. Cephalexin is an option only in compatible susceptible bacterial contexts.
For the detailed oral-versus-topical distinction, consult cephalexin versus mupirocin. For deeper cellulitis or an abscess, use the skin infection hub.
It can be selected for some more extensive cases or ecthyma when susceptible bacteria are likely and the clinician chooses oral treatment.
No. Limited superficial impetigo may be treated with a topical prescription instead.
Mupirocin is topical; cephalexin is oral and systemic. They are not automatically interchangeable.
Some cases can involve resistant staph, which may require different evaluation and treatment.
A clinician may prescribe it for children when appropriate; the exact form and regimen must be individualized.
No. Shared or leftover antibiotics risk incorrect treatment, especially when the illness or concentration differs.
Seek clinical reassessment if they spread significantly, become painful, or are accompanied by fever or illness.
Yes. Oral cephalexin is a prescription medicine in the United States.